Header
For Healthcare Professionals
jardiance-hf-banner 2x-updated-new

Palak, 66

Referred to you by her PCP for cardiac review

Palak-66-image

Not an actual patient.

This material contains AI-generated content.

current-diagnosis-image

Current diagnosis

HFpEF

current-diagnosis-image
Medical history
  • Hypercholesterolaemia
Experiencing-HF-symptoms-image
Experiencing HF symptoms
  • Dyspnoea
  • Oedema
  • NYHA class II, progressing to III
Current-treatment-image
Current treatment
  • Statin
eGFR-key-fact-image
eGFR (mL/min/1.73 m2)

45

Experiencing-HF-symptoms-image
LVEF

55%-60%

Blood-pressure-hf-image
Blood pressure (mmHg)

140/88

Medical-considerations-image
Medical considerations

Add JARDIANCE early to reduce her risk of CV death or HHF

  • *
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF ≤40%).1-3
  • †
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and preserved ejection fraction (LVEF >40%).2
  • CV=cardiovascular; eGFR=estimated glomerular filtration rate; HF=heart failure; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction; HHF=hospitalisation for heart failure; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; PCP=primary care physician.

  1. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. (EMPEROR-Reduced results and the publication’s Supplementary Appendix.)

  2. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. (EMPEROR-Preserved results and the publication’s Supplementary Appendix.)

  3. API dated 19th Jul 2024 (Based on JARDIANCE® approved prescribing information dated 18th Jul 2024).

Until now, treatment in HFpEF has been focused on reducing symptoms and managing comorbidities1

And patients with HFpEF still experience:

CV DEATH

CV DEATH

5-year mortality is 76% among first hospitalised patients2
HOSPITALISATION

HOSPITALISATION

90-day rehospitalisation rate is 30%3
And patients with HFpEF still experience-palak-image

  • CV=cardiovascular; HFpEF=heart failure with preserved ejection fraction; HHF=hospitalisation for heart failure.

  1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368

  2. Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476-2486. doi:10.1016/j.jacc.2017.08.074

  3. Khan MS, Sreenivasan J, Lateef N, et al. Trends in 30-and 90-day readmission rates for heart failure. Circ Heart Fail. 2021;14(4):e008335. doi:10.1161/CIRCHEARTFAILURE.121.008335

JARDIANCE is the first clinically proven and approved therapy to treat HFpEF1-10

Treatments proven*† to reduce the risk of CV death or HHF

Treatments proven-palak image
Treatments proven-palak image

Antihypertensives are effective in certain comorbidities. Diuretics are effective at reducing symptoms of congestion.

* Proven=meeting the primary endpoint in clinical trials.

  • †
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF ≤ 40%).
  • Adult patients with chronic heart failure (NYHA class II, III, or IV) and preserved ejection fraction (LVEF > 40%).11,12
  • ACEi=angiotensin-converting enzyme inhibitor; ARB=angiotensin II receptor blocker; ARNI=angiotensin receptor neprilysin inhibitor; CV=cardiovascular; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction; HHF=hospitalisation for heart failure; LVEF=left ventricular ejection fraction; MRA=mineralocorticoid receptor antagonist; NYHA=New York Heart Association.

  1. Granger CB, McMurray JJV, Yusuf S, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772-776. doi:10.1016/S0140-6736(03)14284-5

  2. Yusuf S, Pfeffer MA, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 2003;362(9386):777-781. doi:10.1016/S0140-6736(03)14285-7

  3. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN; SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302. doi:10.1056/NEJM199108013250501

  4. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338-2345. doi:10.1093/eurheartj/ehl250

  5. Massie BM, Carson PE, McMurray JJ, et al; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456-2467. doi:10.1056/NEJMoa0805450

  6. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. doi:10.1056/NEJMoa1009492

  7. Pitt B, Zannad F, Remme WJ, et al; Randomised Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-717. doi:10.1056/NEJM199909023411001

  8. Pitt B, Pfeffer MA, Assmann SF, et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-1392. doi:10.1056/NEJMoa1313731

  9. McMurray JJV, Packer M, Desai AS, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077

  10. Solomon SD, McMurray JJV, Anand IS, et al; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609-1620. doi:10.1056/NEJMoa1908655

  11. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190 (EMPEROR-Reduced results and the publication’s Supplementary Appendix.)

  12. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 (EMPEROR-Preserved results and the publication's Supplementary Appendix.)

hf-patient-care-jardiance-heart-cv-image

In the treatment of patients with HF with LVEF >40%*

JARDIANCE protected patients by reducing the risk of CV death or HHF†1
patient-profile-palak-graph-1
patient-profile-palak-graph-1

Results from the EMPEROR-Preserved trial.

hf-patient-care-jardiance-heart-cv-image

In the treatment of patients with HF with LVEF ≤40%*

JARDIANCE protected patients by reducing the risk of first and recurrent hospitalisation for HF¶1
patient-prifile-palak-graph-2
patient-prifile-palak-graph-2

Results from the EMPEROR-Preserved trial.

  • *
    Adult patients with chronic heart failure (NYHA class II, III, or IV) and reduced ejection fraction (LVEF ≤40%).1
  • †
    In the EMPEROR-Preserved trial, a randomised, double-blind, parallel-group, placebo-controlled study of 5988 patients with HFpEF, the efficacy and safety of JARDIANCE 10 mg (n=2997) were evaluated vs placebo (n=2991). The primary endpoint in the EMPEROR-Preserved trial was a composite of CV death or HHF, analysed as time to the first event. Patients treated with JARDIANCE experienced a 21% RRR in this endpoint (HR=0.79; 95% CI: 0.69, 0.90; p<0.001).1
  • ‡
    ARR calculation: JARDIANCE number of patients with events 415/total number of patients 2997=13.8%; placebo number of patients with events 511/total number of patients 2991=17.1%; 17.1%–13.8%=3.3%. NNT=1/ARR.1
  • §
    Reduction in the risk of CV death or HHF.2
  • II
    Background treatment: All appropriate treatments for heart failure or comorbid conditions could be initiated or altered at the discretion of the clinician.1
  • The occurrence of all HHF, including first and recurrent events, was a prespecified secondary outcome of the EMPEROR-Preserved trial.1

  1. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. (EMPEROR-Preserved results and the publication’s Supplementary Appendix.)

  2. Butler J, Siddiqi TJ, Filippatos G, et al. Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved Trial. Eur J Heart Fail. 2022;24(2):245-248.

In the treatment of patients with LVEF > 40%*

JARDIANCE has a proven safety and tolerability profile1

JARDIANCE has a proven safety image
JARDIANCE has a proven safety image

  • *
    Adult patients with chronic HF (NYHA class II, III, or IV) and preserved ejection fraction (LVEF >40%).1
  • †
    Hypoglycaemic AEs with a plasma glucose value of ≤70 mg/dL (3.9 mmol/L) or that required assistance.1
  • AE=adverse event; HF=heart failure; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; T2D=type 2 diabetes

  1. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. (EMPEROR-Preserved results and the publication’s Supplementary Appendix.)

PC-IN-103696 Validity till Oct 2025